Company Overview and News

 
'Late out of the blocks': NSW lags Victoria, other states in renewables

2018-10-15 smh.com.au
NSW trails most of the nation in adding new renewable energy, sourcing just six per cent of electricity from wind or solar, and lacking a target to drive faster penetration, a new study by the Climate Council has found.
GNX

 
Energy storage must be at heart of our future grid, Alan Finkel says

2018-07-06 theage.com.au
Chief Scientist Alan Finkel says Australia is taking a world-leading position in energy storage – beyond just batteries – and must put the technology at the centre of its own energy transition.
GNX

 
Energy storage must be at heart of our future grid, Alan Finkel says

2018-07-06 smh.com.au
Chief Scientist Alan Finkel says Australia is taking a world-leading position in energy storage – beyond just batteries – and must put the technology at the centre of its own energy transition.
GNX

 
Genex Power Ltd set to finalise 'some major milestones' in next six months

2018-06-29 proactiveinvestors.com.au
Genex Power Ltd (ASX:GNX) executive director Simon Kidston tells Proactive Investors all the latest regarding the development of The Genex Kidston Renewable Energy Hub in north Queensland. The renewable energy generation and storage company is in the midst of developing the project in three stages.
GNX

 
Coal-linked government fund pumps $500m into QLD renewable project

2018-06-20 theage.com.au
Genex Power’s Queensland-based Kidston pumped hydro storage and solar project has received more than $500 million from a government infrastructure fund that has previously drawn flak as a facility to prop up coal projects.
GNX

 
Coal-linked government fund pumps $500m into QLD renewable project

2018-06-20 smh.com.au
Genex Power’s Queensland-based Kidston pumped hydro storage and solar project has received more than $500 million from a government infrastructure fund that has previously drawn flak as a facility to prop up coal projects.
GNX

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:GNX / GENEX POWER LIMITED on message board site Silicon Investor.

MGNX -- MacroGenics MGNX -- MacroGenics MGNX -- MacroGenics Zogenix - ZGNX Zogenix - ZGNX Zogenix - ZGNX
VGNX -- Variagenics, Inc. VGNX -- Variagenics, Inc. VGNX -- Variagenics, Inc. VGNX: Variagenics, Inc. VGNX: Variagenics, Inc. VGNX: Variagenics, Inc.
CGNX, NIS, BRCD, AHP, SCH, LU, CSCO, TDY Articles CGNX, NIS, BRCD, AHP, SCH, LU, CSCO, TDY Articles CGNX, NIS, BRCD, AHP, SCH, LU, CSCO, TDY Articles Lignex--(LGNX-OTC) Lignex--(LGNX-OTC) Lignex--(LGNX-OTC)
Genomics One Corporation (gnx) Genomics One Corporation (gnx) Genomics One Corporation (gnx) Cognex (CGNX-OTC) Did you know... Cognex (CGNX-OTC) Did you know... Cognex (CGNX-OTC) Did you know...